诊疗一体化在物理靶向核素治疗中的应用现状及展望

The current status and prospects of theranostic in targeted radionuclide therapy

靶向放射性核素治疗(targeted radionuclide therapy,TRT)指通过各种手段使放射性药物在肿瘤组织内聚集的治疗方式。基于治疗方式的不同,TRT可分为化学/生物靶向内照射治疗与物理靶向内照射治疗。TRT一般指全身给药的化学/生物靶向核素治疗。随着核医学诊断治疗技术的不断发展和精准医学的推进,临床上已将分子影像与物理靶向核素治疗相结合,形成诊疗一体化的物理靶向核素治疗。本文以目前临床常见和新兴的物理靶向核素治疗为例,介绍诊疗一体化在物理靶向核素治疗中的应用现状及发展趋势。

Targeted radionuclide therapy(TRT)leveraging the unique properties of radioactive pharmaceuticals to concentrate therapeutic effects within tumor tissues.TRT can be principally categorized into two distinct approaches based on the differences in targeting mechanisms:chemical/biological targeting internal radiotherapy and physical targeting internal radiotherapy.Generally,TRT refers to the systemic administration of targeted radionuclide drugs.The continuous advancement of nuclear medicine diagnostic and therapeutic technologies,coupled with the advocacy of precision medicine,has led to an innovative integration in clinical practice:integrated physical targeted radionuclide theranostics.This article explored the current status and development of theranostics in physically targeted radionuclide treatment,highlighting some common and emerging therapies in clinical practice.